Meng Chen, MD
Allergy & Immunology · Sugar Land, TXNPI 1932510112
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by GSK at 44.2% of the total. 2025 is the largest year on record at $20,130, more than ten times the $311 reported in 2019. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 705 payments — averaging $59.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- Sanofi$12K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$979
- Grifols USA, LLC$675
- Takeda Pharmaceuticals U.S.A., Inc.$645
- plus $6K from 33 others
What the payments were for
- Consulting fees$8,50820%
- Speaking & faculty fees$15,92538%
- Travel & lodging$8732%
- Food & beverage$16,23339%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 147 | $18,408 |
| Sanofi | 83 | $12,193 |
| AstraZeneca | 100 | $2,669 |
| Regeneron Healthcare Solutions, Inc. | 31 | $979 |
| Grifols USA, LLC | 34 | $675 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $645 |
| Pfizer | 29 | $631 |
| Biocryst US Sales Co., LLC | 43 | $630 |
| CSL Behring | 30 | $608 |
| Amgen(2 entities) | 25 | $474 |
| Optinose US, Inc. | 21 | $428 |
| Novartis | 18 | $392 |
| Teva Pharmaceuticals USA, Inc. | 16 | $391 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $284 |
| Octapharma USA, Inc. | 8 | $280 |
| Kaleo, Inc. | 12 | $251 |
| Blueprint Medicines Corporation | 4 | $224 |
| Alk-abello, Inc | 13 | $191 |
| Incyte Corporation | 8 | $177 |
| Pharming Healthcare, Inc. | 7 | $139 |
| Organon | 4 | $125 |
| Arcutis Biotherapeutics, Inc. | 1 | $104 |
| Genentech, Inc. | 1 | $91 |
| Aimmune Therapeutics, Inc. | 4 | $83 |
| Hospira, Inc. | 3 | $67 |
| Galderma Laboratories, L.p. | 4 | $65 |
| LEO Pharma Inc. | 3 | $63 |
| Hikma Pharmaceuticals USA | 3 | $61 |
| Aytu Biopharma, Inc. | 3 | $54 |
| Shire North American Group Inc | 2 | $50 |
| Mylan Pharmaceuticals Inc. | 2 | $39 |
| Genentech USA, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,611 in reported general payments places this provider in the 90th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 38 | $107,518 |
| NucalaMepolizumab | 24 | $88,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $54,758 |
| Dupixent PenDupilumab | 12 | $44,235 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $17,031 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,611 |
| Azelastine Hcl | 216 | $7,659 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $6,138 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,248 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,769 |
| BreynaBudesonide/Formoterol Fumarate | 28 | $4,560 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $3,364 |
| Epinephrine | 16 | $3,302 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,940 |
| Levocetirizine Dihydrochloride | 248 | $2,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $18,408 | $160,153121 claims |
| Genentech, Inc.Xolair | $91 | $107,51838 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,669 | $17,86034 claims |
| Hikma Pharmaceuticals USAEpinephrine | $61 | $3,30216 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $16 | $34926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Sugar Land
- David AmranSugar Land$109K
- Nerissa D'silvaSugar Land$31K
- John KelleySugar Land$24K
- Vikas KancherlaSugar Land$21K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.